Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dan Hung Barouch, M.D.

Co-Author

This page shows the publications co-authored by Dan Barouch and Kathryn Stephenson.
Connection Strength

12.935
  1. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021 04 20; 325(15):1535-1544.
    View in: PubMed
    Score: 0.973
  2. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2020 09; 20(9):1061-1070.
    View in: PubMed
    Score: 0.910
  3. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Annu Rev Immunol. 2020 04 26; 38:673-703.
    View in: PubMed
    Score: 0.909
  4. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). Lancet HIV. 2020 06; 7(6):e410-e421.
    View in: PubMed
    Score: 0.897
  5. First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS One. 2018; 13(11):e0205139.
    View in: PubMed
    Score: 0.822
  6. New concepts in HIV-1 vaccine development. Curr Opin Immunol. 2016 08; 41:39-46.
    View in: PubMed
    Score: 0.694
  7. Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. Open Forum Infect Dis. 2016 Apr; 3(2):ofw100.
    View in: PubMed
    Score: 0.692
  8. Broadly Neutralizing Antibodies for HIV Eradication. Curr HIV/AIDS Rep. 2016 Feb; 13(1):31-7.
    View in: PubMed
    Score: 0.678
  9. Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. J Immunol Methods. 2015 Jan; 416:105-23.
    View in: PubMed
    Score: 0.623
  10. A global approach to HIV-1 vaccine development. Immunol Rev. 2013 Jul; 254(1):295-304.
    View in: PubMed
    Score: 0.566
  11. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J Virol. 2012 Nov; 86(21):11434-40.
    View in: PubMed
    Score: 0.533
  12. Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. J Virol. 2012 Sep; 86(18):9583-9.
    View in: PubMed
    Score: 0.529
  13. Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. J Infect Dis. 2012 Jun 15; 205(12):1806-10.
    View in: PubMed
    Score: 0.520
  14. Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination. N Engl J Med. 2021 09 02; 385(10):951-953.
    View in: PubMed
    Score: 0.247
  15. Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19. medRxiv. 2021 Jul 07.
    View in: PubMed
    Score: 0.247
  16. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021 08; 596(7871):268-272.
    View in: PubMed
    Score: 0.245
  17. A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. Ann Intern Med. 2021 05; 174(5):585-594.
    View in: PubMed
    Score: 0.240
  18. Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. Cell. 2020 11 25; 183(5):1354-1366.e13.
    View in: PubMed
    Score: 0.234
  19. Zika virus vaccines. Nat Rev Microbiol. 2018 10; 16(10):594-600.
    View in: PubMed
    Score: 0.204
  20. Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys. J Virol. 2018 08 01; 92(15).
    View in: PubMed
    Score: 0.201
  21. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 07 21; 392(10143):232-243.
    View in: PubMed
    Score: 0.200
  22. Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol. 2018 07 01; 92(13).
    View in: PubMed
    Score: 0.200
  23. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature. 2016 12 08; 540(7632):284-287.
    View in: PubMed
    Score: 0.179
  24. Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function. Sci Immunol. 2016 Nov; 1(5).
    View in: PubMed
    Score: 0.179
  25. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016 09 09; 353(6304):1129-32.
    View in: PubMed
    Score: 0.175
  26. Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization. Clin Vaccine Immunol. 2015 Nov; 22(11):1166-75.
    View in: PubMed
    Score: 0.165
  27. Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeys. J Virol. 2014 Nov; 88(22):13510-5.
    View in: PubMed
    Score: 0.154
  28. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013 Nov 14; 503(7475):224-8.
    View in: PubMed
    Score: 0.145
  29. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013 Oct 24; 155(3):531-9.
    View in: PubMed
    Score: 0.145
  30. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021 05 13; 384(19):1824-1835.
    View in: PubMed
    Score: 0.060
  31. HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. Cell Rep. 2020 12 15; 33(11):108502.
    View in: PubMed
    Score: 0.059
  32. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nat Med. 2020 02; 26(2):228-235.
    View in: PubMed
    Score: 0.056
  33. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 08 14; 26(2):296.
    View in: PubMed
    Score: 0.054
  34. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 04; 6(4):e259-e268.
    View in: PubMed
    Score: 0.053
  35. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 01 09; 25(1):59-72.e8.
    View in: PubMed
    Score: 0.052
  36. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 07 13; 218(4):633-644.
    View in: PubMed
    Score: 0.050
  37. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 02 10; 391(10120):563-571.
    View in: PubMed
    Score: 0.048
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.